Real-life Effectiveness of Vortioxetine in Depression
Public ClinicalTrials.gov record NCT03555136. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Real-life Effectiveness of Vortioxetine in Patients With Major Depressive Disorder: Non-interventional, Multi-national, Prospective Cohort Study to Assess Real-life Effectiveness of Vortioxetine
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Worldwide Major Depressive Disorder (MDD) has significant negative personal, societal and economic consequences. Vortioxetine (Brintellix®) is a new antidepressant authorized since 2013. Despite evidence generated from clinical trials which demonstrate that vortioxetine is an efficacious, well-tolerated antidepressant, there is a need to determine the effectiveness of vortioxetine in real life routine practice. The study aim is to examine the real-life effectiveness of vortioxetine on functioning, depressive symptom relief, cognition and quality of life. This is an observational, multi-national, study in patients with MDD initiating treatment with vortioxetine. Information will be collected by the physician, from the patient and their medical record at three time points - baseline, week 12 and week 24 (end of follow-up). This study will be conducted in six countries. In total 2,100 patients are planned for enrolment.
Study identification
- NCT ID
- NCT03555136
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 992 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 17, 2017 (Actual)
- Primary completion
- Jan 31, 2021 (Actual)
- Completion
- Jan 31, 2021 (Actual)
- Last update posted
- May 27, 2021
2017 – 2021
United States locations
- U.S. sites
- 31
- U.S. states
- 17
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Harmonex Neuroscience Research Inc (US0072) | Dothan | Alabama | 36303 | — |
| Center For Advanced Improvement (US0011) | Tucson | Arizona | 85719 | — |
| Pharmacology Research Institute (US0045) | Newport Beach | California | 92660 | — |
| North County Clinical Research (Nccr) (US0071) | Oceanside | California | 92054 | — |
| Breakthrough Clinical Trials (US0074) | San Bernardino | California | 92408 | — |
| Viking Clinical Research Center LLC (US0033) | Temecula | California | 92591 | — |
| Da Vinci Research Institute (US0063) | Boca Raton | Florida | 33487 | — |
| Sarkis Clinical Trials (US0066) | Gainesville | Florida | 32607 | — |
| Maxblue Institute (US0038) | Hialeah | Florida | 33018 | — |
| Office Of Amit Vijapura, Md (US0057) | Jacksonville | Florida | 32256 | — |
| International Research Associates LLC (US0060) | Miami | Florida | 33183 | — |
| Millenia Psychiatry and Research, Inc. (US0015) | Orlando | Florida | 32839 | — |
| Professional Health Care of Pinellas (US0050) | St. Petersburg | Florida | 33713 | — |
| Northwest Behavioral Research Center (US0007) | Marietta | Georgia | 30060 | — |
| Pearl Health Clinic (US0001) | Ammon | Idaho | 83406 | — |
| Southern Illinois Associates LLC (US0079) | Glen Carbon | Illinois | 62034 | — |
| AMR- Baber Research, Inc. (US0006) | Naperville | Illinois | 60563 | — |
| University Of Kansas Cancer Center (US0078) | Kansas City | Kansas | 66160 | — |
| Neuroscientific Insights (US0029) | Rockville | Maryland | 20852 | — |
| Rochester Center For Behavioral Medicine (US0059) | Rochester Hills | Michigan | 48307 | — |
| St. Charles Psychiatric Associates - Midwest Research Group (US0039) | Saint Charles | Missouri | 63304 | — |
| Alivation Research, LLC (US0020) | Lincoln | Nebraska | 68526 | — |
| Meridian Clinical Research (US0027) | Norfolk | Nebraska | 68701 | — |
| Finger Lakes Clinical Research (US0005) | Rochester | New York | 14618 | — |
| Quest Therapeutics Of Avon Lake (US0002) | Avon Lake | Ohio | 44012 | — |
| Psychiatric Consultants, Pc (US0028) | Franklin | Tennessee | 37067 | — |
| Bay Pointe Behavioral Health (US0030) | Friendswood | Texas | 77546 | — |
| Biopharma Informatic, LLC (US0031) | Houston | Texas | 77084 | — |
| Biopharma Informatic, LLC | Houston | Texas | 77084 | — |
| West park Springs (US0073) | Richmond | Texas | 77407 | — |
| Core Clinical Research (US0067) | Everett | Washington | 98201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 75 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03555136, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 27, 2021 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03555136 live on ClinicalTrials.gov.